The biopharmaceutical and health industries are strategic emerging industries that are vital to the national economy, people’s livelihoods, and national security, and public health is an important hallmark of socialist modernization.To thoroughly implement the work arrangements of the Municipal Party Committee and Municipal Government regarding the construction of the “12218” modern industrial system and the “development of a high-end biopharmaceutical manufacturing growth pole in the northern region,” leverage our proximity to the airport to accelerate the clustering of high-end biopharmaceutical and health manufacturing enterprises, promote the high-quality development of the biopharmaceutical and health industries, and expedite the formation of new-quality productive forces, these measures are formulated in accordance with the “Guiding Opinions of the General Office of the State Council on Promoting the Healthy Development of the Pharmaceutical Industry” (State Council General Office Document [2016] No. 11),the “Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Drug and Medical Device Supervision and Promoting the High-Quality Development of the Pharmaceutical Industry” (State Council General Office Document [2024] No. 53), and in light of the actual conditions of our district, these measures are hereby formulated.
I. Key Supported Industrial Sectors
High-end Medical Equipment Manufacturing: Including R&D of raw materials and products (electronic components, medical materials, product development, etc.), medical devices, home medical equipment, in vitro diagnostic devices, and high-value medical consumables;
Biopharmaceutical Manufacturing: Including vaccines, cell therapies, immunological products, antibody drugs, and radiopharmaceuticals;
Healthcare Sector: Including medical rehabilitation, medical aesthetics and supporting testing and inspection services, nutritional health foods and products, etc.;
Pharmaceutical Contract Outsourcing Service Platforms: Including pilot-scale production platforms, high-end formulation platforms, Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and Contract Development and Manufacturing Organizations (CDMOs), etc.
II. Attract a Group of High-Quality Enterprises
Vigorously attract leading enterprises. Focusing on key support sectors and leveraging the location advantages of the airport hub, we will attract a cluster of pharmaceutical and medical device manufacturing enterprises with an airport-oriented focus. For manufacturing projects with pre-production fixed-asset investments (excluding land acquisition costs, as below) of no less than 300 million yuan, a one-time subsidy of 20% of the total fixed-asset investment will be provided, with a maximum subsidy of 80 million yuan per project.At the same time, comprehensive support will be provided in terms of spatial allocation, site construction, and equipment procurement, and dedicated service channels will be established for enterprises’ product imports and exports. (Responsible Units: Huadu Development Zone Management Committee, District Bureau of Science, Technology, Industry, and Information Technology, Huadu Branch of the Municipal Bureau of Planning and Natural Resources, District Market Supervision Bureau, District Health Bureau)
III. Supporting the Development of New Fields and New Growth Areas
Focusing on new fields and sectors in biomedicine and health, we will vigorously attract a batch of high-value, high-potency, and highly effective R&D projects—including those in biosensing, synthetic biology, vaccines, cell therapies, immunological products, antibody drugs, and gene therapy drugs—as well as new drug R&D institutions and public technology service platforms for biomedicine. For projects with fixed-asset investments of no less than 80 million yuan, a one-time subsidy of 20% of the total fixed-asset investment will be provided, with a maximum subsidy of 40 million yuan per project.(Responsible Units: Huadu Development Zone Management Committee, District Bureau of Science, Technology, Industry, and Information Technology, District Market Supervision Bureau, District Health Bureau)
IV. Promoting Industrial Cluster Development
Support enterprises in expanding and strengthening their operations. For biopharmaceutical manufacturing enterprises whose annual industrial output value reaches 30 million yuan, 50 million yuan, or 100 million yuan for the first time, support of 30,000 yuan, 50,000 yuan, or 100,000 yuan will be provided, respectively. For biopharmaceutical R&D service enterprises whose annual operating revenue reaches 10 million yuan, 20 million yuan, or 50 million yuan for the first time, support of 100,000 yuan, 200,000 yuan, or 500,000 yuan will be provided, respectively.(Responsible Units: District Bureau of Science, Technology, Industry, and Information Technology; District Market Regulation Bureau; District Health Bureau; District Finance Bureau)
Supporting Enterprise Innovation and Development. Newly designated national-level “Single Champion” manufacturing enterprises, “Specialized, Refined, Unique, and Innovative” (SRUI) enterprises, or “Little Giant” enterprises will receive a one-time grant of up to 500,000 yuan; newly designated provincial-level “Single Champion” manufacturing enterprises or SRUI small and medium-sized enterprises will receive a one-time grant of up to 100,000 yuan; and newly designated unicorn enterprises will receive a one-time grant of up to 3 million yuan. (Responsible Unit: District Bureau of Science, Technology, Industry, and Information Technology)
V. Strengthening Industrial Infrastructure Support
Develop specialized biopharmaceutical and health parks. Adhering to the principle of “global R&D and innovation, local commercialization in Huadu,” we will fully leverage the role of district-owned state-owned enterprises to plan and construct a series of “1,000-mu, 10-billion-yuan” biopharmaceutical and health industrial parks from the outset, establishing Huadu as the premier destination for the commercialization of high-level scientific and technological innovations;Strengthen the synchronization of park development and investment promotion, vigorously attracting leading enterprises in key sectors such as medical devices, health foods, modern traditional Chinese medicine, precision medicine, in vitro diagnostics, and health services, as well as their core business divisions and regional headquarters, to settle in Huadu. This will build a distinctive biopharmaceutical and health industry chain with significant economic benefits, achieving “synergistic collaboration and complementary development” with Guangzhou International Bio-Island.For projects with land requirements, flexible land supply methods will be piloted, with the starting price for land grants set at 70% of the appraised value. For high-quality projects characterized by high technological content, strong driving force, and promising development prospects, within the scope permitted by policy, we will further liberate our thinking and implement customized land preferential policies to minimize initial land acquisition costs to the greatest extent possible, thereby facilitating the rapid implementation and efficient development of these projects.[Responsible Units: Huadu Development Zone Management Committee, District Finance Bureau, Huadu Branch of the Municipal Planning and Natural Resources Bureau, District Housing and Urban-Rural Development Bureau, and all towns (subdistricts)]
Specialized Supporting Measures.Support enterprises and park management agencies in establishing specialized biopharmaceutical and health parks. Adopt an industrial supply model of “low-cost development + high-quality construction + near-cost provision.” Tailor factory construction services to meet the specific requirements of enterprises at different stages—from pharmaceutical laboratory research and small-batch trial production to pilot and industrial-scale manufacturing—including building ceiling heights and load-bearing capacities. Provide nearby infrastructure such as roads, water supply, sewage disposal, drainage, telecommunications fiber-optic cables, and power supply.For enterprises entering the park, ensure the supply of wastewater discharge quotas for construction projects and introduce qualified professional institutions to provide storage and disposal services for hazardous materials in the biopharmaceutical sector. [Responsible Units: Huadu Branch of the Municipal Bureau of Planning and Natural Resources, District Bureau of Housing and Urban-Rural Development, District Water Affairs Bureau, Huadu Branch of the Municipal Bureau of Ecology and Environment, District Bureau of Science, Technology, Industry, and Information Technology, Huadu Development Zone Management Committee, and all towns (subdistricts)]
Provide rent support. Encourage state-owned enterprises to develop and build incubators, creating “move-in-ready” zero-rent accelerators and incubators. For innovation and entrepreneurship projects with strong innovation capabilities and good market potential, provide free premises for a period not exceeding three years, with a maximum annual support of 1 million yuan per enterprise. At the same time, implement new models such as “equity-for-rent” and “services-for-rent,” offer a series of distinctive services including shared laboratories and exhibition halls, and continuously foster a favorable environment for innovation support.[Responsible Units: Huadu Development Zone Management Committee, District Finance Bureau, all towns (subdistricts)]
VI. Targeted Expansion of Application Scenarios
Promote the coordinated development of hospitals and enterprises. Support the inclusion of the Huadu Campus of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, the Guangdong Provincial Institute of Traditional Chinese Medicine Clinical Research, the Huadu Campus of Guangzhou Women and Children’s Medical Center, and district-level hospitals as designated medical institutions under the Hong Kong-Macao Medical Devices and Pharmaceuticals Access Program. Encourage district-level medical institutions to join the Guangzhou Research-Oriented Hospital Alliance, fully leveraging the alliance’s role in “coordination, collaboration, and empowerment” to comprehensively enhance capabilities in clinical research and the commercialization of innovative medical devices and pharmaceuticals, thereby promoting the use of more clinically urgent drugs within regional medical institutions.Incorporate clinical research into the performance evaluation indicators of tertiary public hospitals. Encourage district medical institutions with drug clinical trial qualifications to sign clinical trial cooperation agreements with pharmaceutical companies, providing clinical trial services to biopharmaceutical enterprises annually. Improve the industry-academia-research mechanism by establishing a government-led regular exchange mechanism among medical institutions, universities, and enterprises. Deepen full-industry-chain collaboration between hospitals and enterprises, and encourage local hospitals to establish industry-academia-research transformation institutes. Support the brain-computer interface project at the Huadu Campus of Sun Yat-sen Memorial Hospital, Sun Yat-sen University,and facilitate the commercialization of research projects from the District People’s Hospital’s Departments of Gastroenterology and Nephrology/Urology, the Municipal Hospital of Integrated Traditional and Western Medicine’s Department of Critical Care Medicine, and the District Maternal and Child Health Hospital’s specialized departments for prenatal care and neonatal care. This will achieve the sustainable development of a “clinical-research-clinical” closed-loop and the full-chain transformation from “proof of concept to clinical trials to industrialization.” (Responsible Units: District Health Bureau, District Market Regulation Bureau, District Education Bureau)
Expand sales channels for pharmaceuticals and medical devices. Provide full support for pharmaceutical companies to include their products in the Group Purchasing Organization (GPO) platform to open up sales markets. Vigorously promote pharmaceutical companies’ participation in negotiations for national, provincial, and municipal medical insurance drug lists, as well as centralized volume-based procurement of pharmaceuticals and medical devices, ensuring that more products are included in medical insurance coverage and volume-based procurement through negotiations.Promptly recommend enterprises’ innovative drugs—including first-in-class or best-in-class medications—as well as Class III medical devices for inclusion in Guangzhou’s Major Innovative Drug and Medical Device Product Catalog. Establish a procurement incentive system for catalog products and urge medical institutions in our district to ensure “full procurement of all eligible items.”(Responsible Units: District Health Bureau, District Bureau of Science, Technology, Industry, and Information Technology, District Market Regulation Bureau, Huadu Branch of the Municipal Medical Insurance Service Center, District Commerce Bureau, District Council for the Promotion of International Trade)
VII. Building a Hub for Medical Aesthetics
Leverage the “hub advantage” of the airport, the “brand influence” of high-level specialized hospitals such as the Huadu Campus of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, and the strengths of Huadu’s comprehensive cell bank in research and clinical translation to innovate a model that integrates medicine with pharmaceuticals, medical devices, and aesthetic medicine.Centered around the Huadu Campus of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, create specialty demonstration streets for medical aesthetics and medical rehabilitation. Vigorously support the introduction of enterprises related to medical aesthetics, post-surgical rehabilitation, and cell and gene therapy. Precisely address new consumer demands in medical aesthetics—such as post-surgical repair and reconstruction, microneedle therapy, and facial aesthetics—to drive the clustering of upstream and downstream enterprises.Medical aesthetics institutions (enterprises) newly accredited by the Joint Commission International (JCI) will receive support of up to 20% of their total project investment, with a maximum of 10 million yuan, to establish Huadu’s new flagship “Beauty and Health Industry.” (Responsible Units: Huadu Development Zone Management Committee, District Health Bureau, District Market Supervision Bureau, Huadu Branch of the Municipal Planning and Natural Resources Bureau, Xinya Subdistrict)
VIII. Enhancing Innovation and R&D Capabilities
Support the R&D of innovative pharmaceuticals. For biological products, Class 1 traditional Chinese medicines, Class 2 high-end traditional Chinese medicines, Class 1 chemical drugs, and Class 2 high-end chemical drugs (the classification and definition rules for innovative drugs will be adjusted in a timely manner according to the drug registration classification standards issued by the National Medical Products Administration) independently developed and commercialized by enterprises, support will be provided in phases for the clinical trial research conducted by the enterprises.New drug projects initiating Phase I, II, or III clinical trials will, upon review, receive funding support of up to 3 million yuan, 5 million yuan, and 10 million yuan, respectively. The total annual clinical trial funding received by an enterprise shall not exceed 100 million yuan. (Responsible Units: District Bureau of Science, Technology, Industry, and Information Technology; District Market Regulation Bureau; District Health Bureau)
Support the R&D and production of medical devices. For Class III medical devices developed within the district that obtain their first registration certificate and are commercialized (Class III medical device registration classification shall follow the current registration classification standards issued by the competent national drug regulatory authorities), a one-time grant of up to 1 million yuan will be provided for each product. The cumulative annual support funds received by a single enterprise shall not exceed 5 million yuan. (Responsible Units: District Bureau of Science, Technology, Industry, and Information Technology; District Market Supervision Bureau; District Health Bureau)
Support for the Introduction of New Imported Drugs. For new drug varieties exclusively imported that demonstrate significant clinical advantages and promising market prospects, upon obtaining a drug registration certificate from the National Medical Products Administration, support of up to 12 million yuan will be provided for each variety, equivalent to 10% of the actual investment costs. (Responsible Units: District Market Regulation Bureau, District Bureau of Science, Technology, Industry, and Information Technology, District Health and Health Bureau)
IX. Strengthening Financial Support
Establish the Huadu District Biomedical Industry Development Guidance Special Fund to strengthen investment-driven attraction. Support the biomedical industry in accordance with market principles, encourage private equity funds to increase equity investments in the sector, and guide capital toward early-stage, small-scale, and technology-driven ventures. Fully leverage the guiding and catalytic role of state-owned industrial funds and improve their investment management mechanisms. Establish long-term performance evaluation and error-tolerance mechanisms for projects funded by state-owned funds, transforming state capital into more responsible long-term and patient capital.Encourage banking institutions to innovate and launch personalized products and services tailored to the financing needs of biopharmaceutical and health enterprises; open fast-track channels for credit approval; mobilize and guide eligible enterprises to actively apply for interest subsidy policies at the provincial and municipal levels, and track the progress of applications throughout the entire process.Promote the “Huadu District Guaranteed Loan” program to effectively lower financing barriers and costs for enterprises. Support eligible biopharmaceutical and health industry projects in applying for national treasury bonds and local government special bonds. (Responsible Units: District Development and Reform Bureau, District Finance Bureau, District Commerce Bureau, Huadu Development Zone Management Committee)
X. Strengthening the Recruitment and Cultivation of Industry Talent
Support the recruitment of high-end talent and accelerate the concentration of high-level professionals in the biopharmaceutical and health sectors. For outstanding domestic and international talent recruited by enterprises and relevant institutions, recommend them for application to various municipal and district talent programs in accordance with existing talent policies. Develop the “Huadu District Directory of Critical and Urgently Needed Positions in the Biopharmaceutical and Health Industries,” support the settlement of relevant scarce talent, and provide personalized service guarantees in areas such as housing security, educational counseling, spousal employment, and medical services.Those selected for municipal-level or higher talent programs will be incorporated into the Huadu District High-Level Talent Program to receive service support. Special funds will be allocated annually to expand talent exchange and interaction platforms, supporting industry associations, academic societies, and alliances in organizing high-end exhibitions, forums, and academic conferences in Huadu District. We will broaden the international horizons of talent, support industry professionals in participating in international academic exchanges and competitions, and support their overseas professional training to foster the growth of innovative talent.Relevant rewards will be provided as a 50% matching support based on municipal policy reward amounts, in addition to existing talent policies within the district. (Responsible Units: District Party Committee Organization Department, District Human Resources and Social Security Bureau, District Commerce Bureau, District Science, Technology, Industry, and Information Technology Bureau, District Health Bureau, District Association for Science and Technology, District Federation of Industry and Commerce)
These measures shall take effect upon issuance and remain valid for three years; the implementation period will be dynamically adjusted based on economic conditions and industrial development. Should new regulations be issued at the national, provincial, or municipal levels, implementation shall be adjusted in accordance with those policies.
The terms “not less than,” “reach,” and “not exceed” as used in these measures include the specified number itself.
These measures apply to registered biomedical and health enterprises or institutions that are lawfully engaged in substantive production and business operations within Huadu District, possess sound financial systems, have independent legal person status, operate on an independent accounting basis, and comply with relevant credit management regulations. This primarily includes biomedical enterprises or institutions engaged in research and development, manufacturing, and supporting services in the fields of pharmaceuticals, medical devices, and medical and health services.
Where provisions in these measures overlap, or where this policy overlaps with other industrial policies within the district or supports the same type of initiatives, the principle of “applying the higher benefit without duplication” shall apply. Where support policies exist at the national, provincial, and municipal levels, they shall be applied cumulatively.
